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Objectives. In December 2012, a new technique for treating low-risk prostate cancer was launched at the “Hospital Universitario
Marqués de Valdecilla” (HUMV): the prostate low-dose rate (LDR) brachytherapy. Up to this date, patients from Cantabria choos-
ing this technique were derived to other Autonomous Communities. The objective of this study is to analyze the costs of the
implementation of this technique and compare them to the previous situation.
Methods. We have estimated the costs of the method in collaboration with the “Subdirección de Gestión Económica y Pre-
supuestos” of the HUMV. For the derivation costs we have taken into account travel and maintenance costs as well as the
value of the amount of the prostatic brachytherapy as reﬂected in Annex II from the Order SSI/2687/2012.
Result. The cost of the prostate LDR brachytherapy in the HUMV is 5537D per patient. This value is lower than that included in the
Order SAN 12/2011 for other therapeutic options. The average number of patients derived to other autonomous communities is
50 per year. This has a cost of 10,883D per patient for the Government of Cantabria.
Conclusion. The annual net proﬁt of the implementation of the prostate LDR brachytherapy is 267.300D. The start-up of this
technique has been assumed by the HUMV without any personnel increase and will prevent 50 patients per year from moving
out of Cantabria to undergo this treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.036
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Purpose. Evaluation of interstitial high-dose-rate brachytherapy (HDRBT) both alone and in combination with external beam
radiotherapy (EBRT) recurrent gynecological malignancies in terms of toxicity.
Materials and methods. From 2007 to 2012, 25 women with a mean age of 56 years were treated with transperineal interstitial
HDRBT for recurrent gynecological malignancies. Primary sites included endometrium (4), vulva (2), vagina (5), cervix (14). All
patients were treated with radical intent. Three patients had received radiotherapy before (Median EQD2 [Equivalent Dose to 2Gy
per fraction] = 58.25Gy). Twenty-two patients received EBRT with EQD2 doses between 44 and 50Gy (median, 45Gy) of EBRT. The
HDRBT doses ranged from 3.3 to 11Gy per fraction. Fourteen patients received 1 implant and 11 patients received 2 implants.
One to six fractions per implant were delivered. The total EQD2 for HDRBT was 28Gy (range 14–70). The total (EBRT+HDRBT)
EQD2 was 72Gy (range 35–80).
Results. Median reference volume (Vref) was 100 cm3 (range 42–189). Median volume receiving 150% of the reference dose (V150)
was 30cc (range 10–69). Median volume receiving 200% of the reference volume (V200) was 11cc (range 4–29). EQD2 doses
(EBRT+HDRBT) to the hottest 1cc (D1) and 2cc (D2) in the organs at risk were as follow: median rectum D1=56Gy (3.8–83),
D2=56Gy (3–79). Median bladder D1=56Gy (3.8–90), D2=55Gy (3–90). Acute grade≥3 toxicity was seen in 1 (4%) of the 25 patients
(urinary G4). Late grade≥3 toxicitywas seen in 2 (7.6%) patients (urinary G3, skin G4). No correlationwas seen between dosimetric
parameters and the onset of acute or cronic toxicity.
Conclusion. The use of interstitial HDRBT seems safe for the treatment of recurrent gynecological malignancies. Late toxicity is
not correlated with dosimetric parameters in this series.
http://dx.doi.org/10.1016/j.rpor.2013.03.037
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A 58 year old woman, diagnosed in June 2001 of an endometrial adenocarcinoma G1 stage IIA (cervical superﬁcial) treated
with surgery+external RT+endobronchial brachytherapy. In January 2007 she presents hemoptysis and occasional cough.
Complementary studies were made: Chest CT: the abdominal study only highlights the presence of multiple mesenteric lym-
phadenopathies. MRI: upper left lobe, mass of approx. 5.5 cm, includes the upper lobe bronchus with a mass within its light.
Extension studies were negative for metastases. Bronchoscopy: upper left lobe bronchus an endobronchial mass was observed.
The pathologist reported of a probably metastatic adenocarcinoma compatible and consistent with endometrial origin. In July
